Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. Vrije Universiteit Brussel KU Leuven
Redefining non-inferiority in anamnestic antibody responses using the mean increase of log-transformed antibody titers after revaccination: secondary analysis of a randomized controlled rabies vaccination trial Instituut voor Tropische Geneeskunde
Non-inferiority in the anamnestic antibody response is conventionally determined by comparing seroconversion rates after revaccination. However, this approach is inadequate in the case of high pre-booster antibody titers. Therefore, we propose an alternative method to determine non-inferiority of booster responses. We used anonymized data from a randomized controlled trial (NCT01388985; EudraCT 2011-001612-62) in 500 adults, comparing a ...